MMEDMiniMed Group, Inc.

$19.49

The financials

MiniMed Group, Inc. by the numbers

MiniMed Group, Inc. (MMED) reported revenue of $837M in Q4 2026 (quarter ended April 24, 2026), up 22% from the same quarter a year earlier. That came with a gross margin of 57% and net loss of $185M. For the full year FY2026, revenue was $3.10B (+14% year on year) and net income −$333M. Its largest product in 2026-Q1 was Continuous Glucose Monitoring Systems CGM at $390M, 49% of the disclosed total, just ahead of Consumables at 31%.

MiniMed Group, Inc. income statement, Q4 2026 against the same quarter a year earlier
Income statementQ4 2026Q3 2025Change
Revenue$837M$687M+22%
Gross profit$480M$395M+22%
Operating income−$93M$21Mto a loss
Net income−$185M−$10Mn/a
Diluted EPS−$0.71−$0.04n/a
Revenue by product, 2026-Q1, as reported to the SEC
ProductRevenueShare
Continuous Glucose Monitoring Systems CGM$390M49%
Consumables$244M31%
Pumps$151M19%
Product And Service Other$5.0M0.6%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q1 2026Total $790.0M (+15%)
  • Continuous Glucose Monitoring Systems CGM$390.0MQoQ +18%year on year +18%
  • Consumables$244.0MQoQ +15%year on year +15%
  • Pumps$151.0MQoQ +11%year on year +11%
  • Product And Service Other$5.0MQoQ -38%year on year -38%
Segment sum = 100% of reported consolidated revenue · Latest source: 10-Q filed 2026-04-17, SEC EDGAR